CAJ | 학술논문

目的：通过分析子宫内膜腺癌（endometrial adenocarcinoma，EMA）患者的代谢指标，探讨脂代谢异常与子宫内膜腺癌发生的关系。方法收集68例子宫内膜腺癌患者（内膜癌组）和同期61例正常子宫内膜健康体检者（对照组）的临床资料，检测两组的血脂代谢指标、空腹血糖（fasting plasma glucose，FPG）、空腹血清胰岛素（ fasting serum insulin，FINS）及稳态模型评估的胰岛素抵抗（homeostasis model assessment for insulin resistance，HOMA-IR）水平的差异。采用非条件logistic回归模型分析发生子宫内膜腺癌的危险因素，并探讨其与子宫内膜腺癌临床病理特征的关系。结果内膜癌组的各项血脂指标、FINS和HOMA-IR均高于正常对照组（P均约0.05）；甘油三酯（triglycerides，TG）、FINS、HOMA-IR与子宫内膜腺癌的临床病理特征无明显相关，差异均无统计学意义（P均>0.05）。结论体质指数、腰围、TG、FINS和HOMA-IR与EMA的发生密切相关。FINS、TG升高和存在HOMA-IR可作为子宫内膜腺癌的预测因子。
목적：통과분석자궁내막선암（endometrial adenocarcinoma，EMA）환자적대사지표，탐토지대사이상여자궁내막선암발생적관계。방법수집68례자궁내막선암환자（내막암조）화동기61례정상자궁내막건강체검자（대조조）적림상자료，검측량조적혈지대사지표、공복혈당（fasting plasma glucose，FPG）、공복혈청이도소（ fasting serum insulin，FINS）급은태모형평고적이도소저항（homeostasis model assessment for insulin resistance，HOMA-IR）수평적차이。채용비조건logistic회귀모형분석발생자궁내막선암적위험인소，병탐토기여자궁내막선암림상병리특정적관계。결과내막암조적각항혈지지표、FINS화HOMA-IR균고우정상대조조（P균약0.05）；감유삼지（triglycerides，TG）、FINS、HOMA-IR여자궁내막선암적림상병리특정무명현상관，차이균무통계학의의（P균>0.05）。결론체질지수、요위、TG、FINS화HOMA-IR여EMA적발생밀절상관。FINS、TG승고화존재HOMA-IR가작위자궁내막선암적예측인자。
Objective To explore possible relationships between lipid metabolism disorders and the occurrence of endometrial adenocarcinoma (EMA). Methods A total of 68 patients with EMA and 61 control women were compared in terms of lipid metabolism indicators,fasting plasma glucose (FPG),fasting serum insulin (FINS)and homeostasis model assessment for insulin resistance(HOMA-IR).Pooled odds ratios were estimated using non-conditional logistic regression to identify factors associated with risk of EMA and with clinicopathological features of the disease. Results The lipid indexes,FINS and HOMA-IR differed significantly between patients with EMA and controls (P<0.05).However,triglyceride levels,FINS,and HOMA-IR were not significantly associated with clinicopathological features of EMA (P>0.05). Conclusions EMA occurrence was associated with elevated body mass index, triglycerides,FINS,waist circumference,HOMA-IR.Elevated FINS,triglycerides and HOMA-IR may be useful as predictors of endometrial carcinoma.